Cargando…

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

OBJECTIVE: To assess the efficacy and safety of everolimus in Japanese patients with metastatic renal cell carcinoma. METHODS: A subgroup analysis of the pivotal Phase III, randomized, double-blind, placebo-controlled trial of everolimus 10 mg/day in patients with disease progression after treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukamoto, Taiji, Shinohara, Nobuo, Tsuchiya, Norihiko, Hamamoto, Yasuo, Maruoka, Masayuki, Fujimoto, Hiroyuki, Niwakawa, Masashi, Uemura, Hirotsugu, Usami, Michiyuki, Terai, Akito, Kanayama, Hiro-omi, Sumiyoshi, Yoshiteru, Eto, Masatoshi, Akaza, Hideyuki
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012894/ https://www.ncbi.nlm.nih.gov/pubmed/20965941 http://dx.doi.org/10.1093/jjco/hyq166

Ejemplares similares

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2016)

Unusual trivial trauma may end with extrusion of a well-functioning penile prosthesis: a case report
por: Salama, Nader, et al.
Publicado: (2007)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Down-regulated claudin-7 immunoexpression in urothelial carcinoma of the urinary bladder
por: Gadelmoula, Mohamed, et al.
Publicado: (2013)

High‐level Expression of the CD44 Variant Sharing Exon v10 in Renal Cancer
por: Kan, Masaharu, et al.
Publicado: (1995)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
por: Nishio, Eiji, et al.
Publicado: (2020)

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2023)

Serological Evaluation of Soluble CD44 in Renal Cancer
por: Kan, Masaharu, et al.
Publicado: (1996)

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
por: Eto, Masatoshi, et al.
Publicado: (2015)

Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
por: Kawano, Yoshiaki, et al.
Publicado: (2016)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Experimental pathology by intravital microscopy and genetically encoded fluorescent biosensors
por: Matsuda, Michiyuki, et al.
Publicado: (2020)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Levels of Adiponectin Expression in Peri-Renal and Subcutaneous Adipose Tissue and Its Determinants in Human Biopsied Samples
por: Maimaituxun, Gulinu, et al.
Publicado: (2020)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study
por: Ozono, Seiichiro, et al.
Publicado: (2017)

Granulocyte colony‐stimulating factor producing retroperitoneal leiomyosarcoma
por: Fukuta, Kyotaro, et al.
Publicado: (2020)

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
por: Tada, Kouki, et al.
Publicado: (2022)

Leptomeningeal carcinomatosis in small cell carcinoma of the prostate
por: Fukuta, Kyotaro, et al.
Publicado: (2022)

Prognostic study of acute-on-chronic liver failure patients: Usefulness of the fibrosis-4 index
por: Watanabe, Yusuke, et al.
Publicado: (2022)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

The role of everolimus in liver transplantation
por: Ganschow, Rainer, et al.
Publicado: (2014)

Everolimus in Heart Transplantation: An Update
por: Hirt, Stephan W., et al.
Publicado: (2013)

Use of everolimus in liver transplantation
por: Yee, Mei-Ling, et al.
Publicado: (2017)

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report
por: Kaiho-Sakuma, Michiko, et al.
Publicado: (2018)

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e6mj6qvvgu6v393rvtetlk8hqd